Clinical development failure
The company is still testing investigational therapies, and efficacy or safety setbacks could eliminate program value.
- Scope
- Nivisnebart, latozinemab, and other CNS programs
- Materiality
- high
Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases with high unmet medical need. Its programs are built around disease biology such as misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. The company’s approach combines antibody discovery, protein engineering, and genetically validated targets to try to change disease progression rather than only treat symptoms. Alector also develops its proprietary Alector Brain Carrier (ABC) platform, which is intended to improve delivery of therapeutics across the blood-brain barrier. The company has no approved drugs and currently relies on collaboration revenue, especially from its agreement with GSK, to fund development.
−714,1 %
−679,2 %
−79,1 %
3.83
3.83
| % | |
|---|---|
| Clinical-stage therapeutic programs | 70% Investigational antibody-based programs for neurodegenerative diseases, including nivisnebart and latozinemab. |
| Platform technology | 10% The ABC platform designed to improve delivery of biologics and other modalities across the blood-brain barrier. |
| Collaborative research and development services | 20% R&D services performed under collaboration agreements, primarily with GSK, recognized over the development period. |
Alector does not sell approved medicines today, so its current economic counterparties are collaboration partners...
- Pharmaceutical collaboration partnerprimary
GSK co-develops selected programs, funds part of development, and may commercialize products in and outside the U.S.
- Research and manufacturing partnerssecondary
Specialized third parties such as Adimab and contract manufacturers support discovery, development, and supply execution.
- Future healthcare providers and payorsemerging
If approved, neurologists, hospitals, and payors would buy or reimburse therapies for neurodegenerative disease treatment.
- Patients and caregiversemerging
The eventual end users of therapies for Alzheimer’s disease and other neurodegenerative conditions.
Alector is headquartered in South San Francisco, California, and its business is managed from the United States...
- •Headquartered in South San Francisco, California
- •United States is the key market for shared commercialization economics
- •Outside the United States, GSK controls commercialization and Alector earns royalties
- •Development and manufacturing rely on third-party partners rather than owned plants
- •Global regulatory and supply-chain execution will matter if programs advance
Alector’s strategy is to advance genetically validated programs for neurodegenerative disease while improving the odds...
01
Advance nivisnebart and latozinemab through clinical developmentshort-term
Clinical progress is the main driver of value because the company has no approved products and depends on pipeline success.
02
Expand biomarker-driven development capabilitiesmedium-term
Biomarkers can improve target engagement, patient selection, and the probability of technical success in CNS trials.
03
Preserve capital and extend runwayshort-term
The company needs to fund multi-year R&D while avoiding excessive dilution or premature commercialization spending.
04
Leverage partnerships for development and commercializationmedium-term
External partners reduce the need to build a full commercial organization before product approval.
Alector faces the classic risks of a clinical-stage biotechnology company: no approved products, no product sales, and...
Dependence on collaboration partners
A large portion of expected revenue and development execution depends on GSK and other third parties.
- Scope
- GSK agreement and external R&D/manufacturing partners
- Materiality
- high
Financing and dilution risk
The company expects to need substantial additional funding for R&D and operations beyond current runway.
- Scope
- Future equity, debt, or partnering transactions
- Materiality
- high
Manufacturing and supply-chain risk
Alector relies on contract manufacturers and development manufacturing services rather than owned production assets.
- Scope
- Drug product supply and cGMP compliance
- Materiality
- medium
Commercialization uncertainty
The company has no sales or marketing infrastructure and would need to build or outsource it if products are approved.
- Scope
- Future U.S. and ex-U.S. launch readiness
- Materiality
- medium
Collaboration revenue recognition
Can shift revenue between periods without changing underlying cash receipts
Deferred revenue
Creates a large balance sheet liability and future revenue visibility
Accrued research and development expenses
Can affect quarterly operating loss and comparability
Stock-based compensation
Increases reported operating expenses and reduces comparability to cash burn
CervoMed Inc.
CRVO · Pharmaceutical Preparations
ALUMIS INC.
ALMS · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
BIOVIE INC.
BIVI · Pharmaceutical Preparations
ALX ONCOLOGY HOLDINGS INC
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Xencor Inc
XNCR · Pharmaceutical Preparations
: 11/08/2026